The answer depends on who is taking it, and that is not a dodge — it is the single most important thing to understand about this medication.
Gabapentin’s own FDA-approved label states plainly: “Gabapentin is not a scheduled drug.” It notes that gabapentin “does not exhibit affinity for benzodiazepine, opioid (mu, delta or kappa), or cannabinoid 1 receptor sites” — the places most drugs of abuse do their work. And it describes withdrawal as appearing in “rare postmarketing reports of individuals experiencing withdrawal symptoms shortly after discontinuing higher than recommended doses.”
If that were the whole picture, nobody would be searching this question. But the independent research tells a more complicated story, and the difference between the two is where the real answer lives.
What gabapentin is actually approved for
Gabapentin is approved by the FDA for exactly two things: postherpetic neuralgia in adults — the nerve pain that can follow shingles — and as adjunctive therapy for partial onset seizures in adults and children aged three and over.
That is a narrow list, and it is not why most people are taking it. Gabapentin is prescribed very widely off-label for anxiety, for back pain and other chronic pain, for sleep, for restless legs, and as part of alcohol withdrawal management. Off-label prescribing is legal and often clinically reasonable. But it means a large number of people are taking a medication for a purpose that was never formally studied for approval, which is worth knowing when you are trying to judge your own risk.
What the research actually found
Two numbers explain most of the confusion around this drug.
In the general population, misuse is uncommon. A UK survey found a lifetime misuse prevalence of 1.1% for gabapentin. That is low. For most people holding a gabapentin prescription, this is not a medication that pulls them anywhere.
Among people with opioid use disorder, it is a different drug entirely. Reviews put misuse in that group at 15% to 22%. One study found 26% of patients with an opioid use disorder reported abusing gabapentin, against 4% of patients without one.
That is a six-fold difference, and it is the finding that matters. Gabapentin’s risk is not spread evenly across everyone who takes it. It is concentrated in people who already have a substance use disorder, particularly involving opioids.
The reasons are practical rather than mysterious. Gabapentin appears to potentiate the effect of opioids — making a given amount go further. It is easier to obtain than a scheduled drug. And it is often used to take the edge off when opioids are unavailable or when someone is trying to stop.
Where the euphoria comes from
At prescribed doses, gabapentin does not produce a high. The doses associated with euphoric effects in the literature are far above therapeutic range — reports describe gabapentin misuse above roughly 3,600 mg, with case reports ranging from 1,500 mg all the way to 12,000 mg.
That gap matters. Someone taking 300 mg three times a day for nerve pain is not in the same territory as someone taking ten times that amount to get an effect. The FDA label makes the same distinction, noting that misuse and abuse have been reported particularly among people with a history of polysubstance use who are taking higher-than-recommended doses.
The part that is genuinely dangerous
If there is one thing to take from this article, it is not about addiction. It is about breathing.
The gabapentin label carries this warning: “There is evidence from case reports, human studies, and animal studies associating gabapentin with serious, life-threatening, or fatal respiratory depression when coadministered with CNS depressants, including opioids.”
That warning exists because of a specific review. In December 2019 the FDA issued a drug safety communication after examining 49 cases of gabapentinoid-associated respiratory depression reported between January 2012 and October 2017. Twelve of those 49 people died. In 92% of cases, the person had either a respiratory risk factor — including age-related loss of lung function — or was taking another CNS depressant.
The pattern in the wider literature is the same: gabapentinoid overdose on its own is relatively well tolerated, but “can be lethal if combined with other drugs of abuse, such as opioids and sedatives.”
So the honest risk statement is this. Gabapentin by itself, at prescribed doses, is a low-risk medication for most people. Gabapentin combined with opioids, benzodiazepines, alcohol or other sedatives — particularly by someone with reduced lung function — can kill, and has.
Is it a controlled substance?
Federally, no. But this is one of the few medications where the answer changes depending on where you live. A number of states have added their own controls, scheduling gabapentin at the state level or requiring prescriptions to be reported to a prescription drug monitoring program. The list has both grown and shrunk over the past several years, so it is worth checking the current position in your own state rather than relying on a figure from an article.
The direction of travel is the point: state regulators started paying attention to gabapentin because of what was happening with it in practice, not because of what the federal label says.
Stopping it
Gabapentin should not be stopped abruptly, and this applies whether or not anyone thinks there is a misuse problem. The label instructs that if the dose is reduced, discontinued or substituted, “this should be done gradually over a minimum of 1 week,” and a longer taper may be appropriate.
For people who have been taking large doses, reported withdrawal symptoms include anxiety, agitation, insomnia, sweating, nausea and — in more serious cases — confusion and seizures. The seizure risk is the reason this is a taper worth doing with a prescriber rather than alone, and it is more pressing for anyone taking gabapentin for epilepsy, where stopping suddenly risks seizures independently of any withdrawal effect.
When it is worth raising with someone
The signals here look much like they do with any medication that has started doing a job it was not prescribed for:
- Taking noticeably more than prescribed, or running out consistently early
- Taking it for its effect rather than for the symptom it was prescribed for
- Using it to intensify opioids, alcohol or benzodiazepines, or to manage the gap between them
- Obtaining it outside a prescription
- Having tried to stop and found you could not, or found the symptoms of stopping intolerable
- Being asked about it by a prescriber or pharmacist and finding you would rather not answer
The last one is a better indicator than people give it credit for.
If gabapentin is sitting alongside opioid use, that combination is the thing to address first, and it is the one with the clearest evidence behind it — both for the danger and for the treatments that work. Opioid dependence has effective, well-established treatment, including medically supervised withdrawal and structured care afterwards. Where a prescribed medication has become part of a broader pattern of substance use, treating prescription medication use within recovery is its own clinical question, and one worth asking rather than working around. Where anxiety was the reason for the prescription in the first place, it is worth knowing that the addictiveness of anxiety medication varies enormously by drug class, and gabapentin is not in the same category as a benzodiazepine.
The short version
Gabapentin is not a federally controlled substance and does not act on the receptors most addictive drugs act on. For the large majority of people taking a prescribed dose for a legitimate reason, it is not a medication that produces addiction.
For people with an existing opioid use disorder, the picture is genuinely different: misuse rates run between 15% and 22%, against roughly 1% in the general population. And for anyone combining it with opioids or other sedatives, the risk that matters most is not dependence — it is respiratory depression, which the FDA has documented and which has been fatal.
Stopping should always be tapered. Anyone taking it alongside opioids should have that conversation with a prescriber sooner rather than later.
If you’re struggling with prescription medication use, opioids, or a combination that has become hard to manage, you don’t have to work through it alone. Choice House offers inpatient residential treatment and transitional sober living for men in Boulder, Colorado, with care for co-occurring mental health conditions alongside substance use. Call 720-577-4422 or reach out through our website to talk it through and find out what options might help.